Frank Ingari

Sep 22, 2016

Cure Forward has appointed Frank Ingari as CEO. He has more than 35 years of experience in the consumer, healthcare, and information technology industries. Ingari comes to Cure Forward, from NaviNet where he served as CEO. He has also held CEO appointments at 5-Star Medicare Advantage plan Essence Healthcare and best-in-KLAS value-based care service provider Lumeris, which Ingari co-founded.

Breaking News

Genetic Overlap Between Schizophrenia, Cardiovascular Disease Risk Uncovered by GWAS Analysis
Evvy Closes $14M Series A for Vaginal Microbiome Testing, Launches Add-on STI Screen
Consanguinity Contributes to Common Disease Risk, Study Suggests
Ginkgo Bioworks, Pfizer Ink RNA Drug Discovery Deal Worth up to $331M
MDxHealth, University of Oxford to Assess Prostate Test for Predicting Localized Treatment Outcomes

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.